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Abstract  
Background: Outcomes measured in clinical trials should be meaningful to patients, health 
care professionals and researchers, yet there is heterogeneity in the outcomes used across 
trials. This inconsistency impacts on the ability to compare findings and may mean that the 
results have little importance to health care professionals and the patients that they care 
for. The aim of the present study is to review the outcomes used in registered trials of 
therapies for type 2 diabetes mellitus as the first step in the development of a core outcome 
set for effectiveness trials in type 2 diabetes.  
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Materials and methods: A systematic review of clinicaltrials.gov entries was completed for 
randomised, open (actively recruiting or in follow up period), phase 3 and 4 trials of type 2 
diabetes mellitus in adults.  Trials of; the treatment of diabetes complications; co-
morbidities; prevention; and surgery were excluded.  Each trial was screened for eligibility 
and outcomes extracted from the primary and secondary outcomes data fields and free text 
study information.  The outcomes were recorded verbatim and classified into core outcome 
domains according to the COMET taxonomy.    
Results: 354 trial registrations were reviewed for eligibility and 138 trials included.  A total 
of 1444 outcomes were extracted with a median of 8 outcomes per trial (range 1-60).  
Outcomes were categorised into 30 different outcome domains according to the COMET 
taxonomy, but no single domain or outcome was measured in 100% of trials. The majority of 
trials (88%) included outcomes in the “metabolism and nutrition” domain, such as lipids and 
lipoproteins (21%), HbA1c (18%), hypoglycaemia (14%), fasting plasma/blood glucose (11%), 
glycaemic variability (8%), postprandial response (8%) and insulin sensitivity (5%). Only 10% 
of trials included one or more patient reported outcomes, of these 29% included the 
Diabetes Treatment Satisfaction Questionnaire. 
Conclusions: There is marked heterogeneity in the outcomes measured in registered 
therapeutic intervention trials for type 2 diabetes. The use of an agreed set of core 
outcomes will improve the consistency of reporting in clinical trials for type 2 diabetes.   
Registration: The core outcome set study, of which this is a part, is registered in the COMET 
database, http://www.comet-initiative.org/studies/details/956. 
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Background (150-200) 1 
Type 2 diabetes mellitus accounts for over 90% of all diabetes. It is characterised by abnormal 2 
glucose metabolism brought about by resistance to insulin action and an inadequate compensatory 3 
insulin secretory response [1, 2]. The resulting hyperglycaemia, if left untreated, can lead to both 4 
macrovascular and microvascular complications which may be further exacerbated by obesity, 5 
elevated blood pressure, and dyslipidaemia that are also often associated with type 2 diabetes 6 
mellitus. [3] 7 
 8 
Systematic reviews of glucose lowering treatments for type 2 diabetes have identified inconsistency 9 
in the  outcomes measured and reported and whilst many routinely report glycated haemoglobin, 10 
other measures of glycaemic control and outcomes relating to hypoglycaemia, mortality, diabetes-11 
related complications and quality of life are less frequently reported if at all. [3-8]. The heterogeneity 12 
in  the outcomes used may impact on the translatability of trials into benefits for patients [9, 10]. 13 
The World Health Organisation International Classification of Functioning, Disability and Health (ICF) 14 
core set for diabetes mellitus contains 85 second level categories; 28 of these are included in the 15 
brief ICF core set that the ICF state can be used for the assessment of patients with diabetes 16 
participating in a clinical trial [11, 12]. However,  not only is it impractical to measure all 28 17 
outcomes in the brief ICF core set in all trials, there is also an issue that it just includes outcomes 18 
related to function. Using only the brief ICF core set in clinical trials could mean that other outcomes 19 
important to patients and healthcare professionals, are not measured.  20 
 21 
One suggestion to improve the relevance and consistency of trial outcomes includes the 22 
development of a Core Outcome Set (COS), that represents the minimum set of outcomes that 23 
should be measured and reported in any clinical trial for a given condition, in this case type 2 24 
diabetes[13-15].  To ensure that no COS for trials of type 2 diabetes existed or was in development 25 
by another group a review of entries in the Core Outcome Measures in Effectiveness Trials (COMET) 26 
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initiative database was completed  prior to commencing this project ([16], searched on 21st October 27 
2016 and again prior to manuscript submission on 14-September 2017). No published or ongoing 28 
COS for the treatment of type 2 diabetes without co-morbidity was identified (additional file 1).  29 
 30 
Here we aim to describe the outcomes used in trials, currently recruiting,  evaluating that evaluate 31 
therapeutic interventions for type 2 diabetes, registered in a large international public clinical trial 32 
registry, as the first step in the development of a COS for type 2 diabetes [15]. 33 
Methods   34 
Search strategy 35 
On the 20th October 2016 the ClinicalTrials.gov database ([17]) was searched using the following 36 
search terms: Type 2 diabetes-Type II diabetes – non-insulin dependent diabetes- Open studies - 37 
Interventional studies - Phase 3, 4 - Studies received from 10/11/2007.  38 
 39 
In the context of the clinicaltrials.gov registry, an “open” study is one that is currently recruiting 40 
participants or will be recruiting participants in the future. 41 
 42 
Clinicaltrials.gov was chosen as this registry allows outcomes to be easily identified and extracted 43 
and was the main source of trials in a previous study using trial registries to identify outcomes[7]. 44 
Trials registered prior to 10/11/2007 have been reported elsewhere [7]. 45 
 46 
Eligibility Criteria 47 
Phase 3 and 4 trials of therapeutic interventions for patients with type 2 diabetes were included.   48 
Trials were excluded if they met any of the following criteria: Phase 1 and 2 trials (including entries 49 
listed as phase 2/phase 3); prevention trials; trials of treatment for diabetic foot ulcers, diabetic 50 
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retinopathy, or for diabetic nephropathy; trials of bariatric surgery, and trials of treatment for any 51 
other co-morbidity including non-alchoholic fatty liver disease and cardiovascular disease (trials 52 
assessing cardiovascular safety of glucose lowering drugs are eligible for inclusion).  When trials 53 
were registered more than once, only the initial registration was included.  54 
Assessment of Trial Eligibility  55 
NH and RJ reviewed the first 40 trials together with full discussion about inclusion and exclusion of 56 
trials and outcome extraction. A further 5% of trials was then randomly selected and independently 57 
reviewed in parallel by the reviewers to ensure consistency. Where disagreement was noted the 58 
reviewers discussed the study before reaching a decision. No study required third reviewer 59 
arbitration.  60 
Data extraction 61 
Data on study characteristics was extracted by NH that included trial phase, region, design, type of 62 
intervention (pharmaceutical, nutritional, educational/lifestyle or device) and duration of follow up. 63 
Data on outcomes listed in the clinicaltrials.gov protocol registration entry was extracted by NH and 64 
RJ from the specific outcomes fields and from the study information free text.  Where composite 65 
outcomes were used, all component outcomes were included. Where an outcome was reported in 66 
terms of the measurement instrument used, for example a particular questionnaire, the instrument 67 
was reviewed  and outcomes extracted.  68 
Outcome Classification 69 
NH categorised each outcome according to the COMET taxonomy of core domains [submitted for 70 
publication].  This taxonomy comprises 38 domains under five areas (death, physiological/clinical, 71 
life impact, resource use and adverse events). Functional outcomes were also categorised according 72 
to the ICF top level domains [18].  A random check of categorisation was completed on 30% of 73 
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outcomes by JW, discrepancies were resolved through consensus and discussion with a third 74 
reviewer (PRW) where necessary.  75 
Results  76 
Search results and study characteristics 77 
The search returned 675 entries in the clinicaltrials.gov database, and after duplicates were removed 78 
354 trials were screened for eligibility, of which 138 were included (trial registration numbers of 79 
included trials are available in additional file 2). The flow of included trials is shown in Figure 1.  80 
Of the 138 eligible trials, 127 (92%) were trials of drug interventions with the remainder evaluating 81 
educational or lifestyle (4%), nutritional (2%) or device (1%) interventions.  The majority (65%) were 82 
phase 4 trials with 200 participants or less (median 135, range 12-5000) and follow up of 6 months 83 
of less (median 24 weeks, range 0- 364 weeks). Characteristics of included trials are described in 84 
Table 1.  85 
Classification of trial outcomes 86 
COMET taxonomy 87 
A total of 1444 individual outcomes were extracted with a median of 8 outcomes per trial (range 1-88 
60). Each outcome was reviewed and categorised using the COMET taxonomy (Table 2). 89 
The most frequently included domain was “metabolism and nutrition” with 87% of trials measuring 90 
one or more outcomes in this domain and 92 (67%) trials including an outcome from this domain as 91 
their primary outcome. The key outcomes included in “metabolism and nutrition” were:  outcomes 92 
related to lipids and lipoproteins (21%), HbA1c (18%), hypoglycaemia (14%), fasting plasma/blood 93 
glucose (11%), glycaemic variability (8%), postprandial response (8%) and insulin sensitivity (5%). The 94 
remaining 21% of outcomes were varied and included markers of oxidative and nitrosative stress, 95 
gut hormones, energy expenditure and other non-specific metabolic markers.   96 
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Nearly half of the studies (47%) included outcomes categorised as “general outcomes” (outcomes 97 
that affect the whole body and cannot be attributed to a certain body system) which included 98 
outcomes related to body weight (42%), adiposity (17%), other anthropometric measures (11%), 99 
clinical chemistry not attributed to one particular body function or system (11%), physical activity 100 
(5%), fatigue (3%) and non-specific pain (3%). The remaining 10% of outcomes in the “general 101 
outcomes” category included vital signs, non-specific patient reported outcomes (those with no 102 
detail provided in the clinicaltrials.gov entry other than ‘patient reported outcome’), general health, 103 
smoking status, morbidity and global effectiveness.  104 
Use of Patient Reported Outcome Measures 105 
Fourteen (10%) studies listed one or more patient reported outcome measures (PROMs).  Twenty 106 
three PROMs were identified which measured 68  outcomes (table 3). The use of PROMs was varied 107 
and of the 23 PROMs, 87% were used in only one study. The most frequently used PROM was the 108 
Diabetes Treatment Satisfaction Questionnaire used by four (29%) of the studies reporting PROMs.  109 
ICF core set and outcomes used in registered trials  110 
Of the 1444 individual outcomes, 80 (5.5%) did not fit with any of the ICF categories. These 111 
outcomes included  unspecified adverse events (n=44), treatment preference or satisfaction (n=5), 112 
mortality (n=2), pharmacokinetics (n=1) and general physiological or laboratory measures (n=27).  113 
Ten categories in the ICF brief set and an additional 46 categories in the ICF full core set were not 114 
associated with any outcomes being measured in the trials. The breakdown of outcomes according 115 
to the ICF core set is provided in additional files 3 and 4).  116 
Discussion 117 
There is heterogeneity in the outcomes used across registered open trials for type 2 diabetes. Whilst 118 
some outcomes are commonly measured, and are expected in trials that aim to treat 119 
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hyperglycaemia,  there is no consensus on which outcomes should be routinely measured and 120 
reported, with no single outcome or outcome domain being measured in all trials.  121 
Reaney et al have recently reviewed PROMs used in published phase 3 type 2 diabetes mellitus trials 122 
of GLP-1 receptor agonists, novel insulins, SGLT-2 inhibitors, and DPP-4 inhibitors [19]. The identified 123 
PROMs in the included studies were mixed and varied compared to those identified in the present 124 
review, with overlap of only four measurement instruments (DTSQ, EQ5D, SF-36 and HFS-11 worry 125 
scale). The diabetes treatment satisfaction questionnaire (DTSQ) was the most frequently used 126 
PROM in both the review by Reaney et al and in the present study which may be due to the 127 
recommendations made by the World Health Organisation (WHO) to encourage psychological 128 
wellbeing in patients with diabetes[20]. In the present study only 10% of trials included a PROM; this 129 
is comparable with the study by Barsdorf et al in 2012 who found that only 7.5% of  phase 3 130 
pharmaceutical interventions for type 2 diabetes, registered with clinical trials.gov, included a PROM 131 
[21]. Gandhi et al [7] considered patient important outcomes in registered trials, described as 132 
outcomes that affect the way patients feel, function or survive [8]. In the present study over half 133 
(51%) of trials included one or more outcomes meeting this definition. However, this definition was 134 
not developed with input from patients with type 2 diabetes and so may not truly reflect outcomes 135 
of treatment that they consider to be the most important.  136 
A limitation of the present study is that only one trials registry, clinicaltrials.gov, has been used. 137 
However, in the study by Gandhi et al clinicaltrials.gov was the main registry source accounting for 138 
81% of included studies [7]. In this study only open (actively recruiting or will recruit in the near 139 
future) trials have been included representing the current use of outcomes in trials treating 140 
hyperglycaemia in patients with type 2 diabetes mellitus.   Including only open trials has the 141 
advantage that the outcomes used reflect the current state of affairs in a particular research area.  In 142 
a topic area as vast as type 2 diabetes this has additional importance of not only the resource 143 
needed to review studies and generate an outcomes list but also ensuring that the outcomes 144 
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included in a subsequent Delphi survey are relevant and do not represent outdated and redundant 145 
outcomes.  146 
 147 
A number of core outcome sets exist for type 2 diabetes mellitus in clinical practice but these too 148 
display heterogeneity in included outcomes [22]. The ICF core outcome set [12] was developed using 149 
a consensus process, and was designed for use in clinical practice although it has been suggested 150 
that the brief set of 28 items is suitable for use in clinical trials. However, the ICF set of 28 outcomes 151 
is impractical for use as a COS due to the large number of outcomes and the focus solely on function 152 
which may mean that it does not contain other outcomes important to patients with diabetes and 153 
health professionals caring for them.   154 
This review of current registered trials highlights the need for a COS for use in clinical trials of type 2 155 
diabetes; itand will contribute to a preliminary list of outcomes and outcome domains for use in the 156 
first round of an online Delphi survey to identify which outcomes are of importance to researchers, 157 
health care professionals and patients.  158 
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Tables 202 
 203 
Table 1 Description of included trials 
 N (%) 
Year  
2009 1 (1) 
2010 0 (0) 
2011 2 (1) 
2012 3 (2) 
2013 6 (4)  
2014 21 (15) 
2015 49 (36) 
2016 56 (41) 
  
Phase  
3 48 (35) 
4 90 (65) 
 
Planned enrolment (median and 
range) 
135 (12-5000) 
 
Region of worka 
Asia 55 (40) 
Europe 45 (33) 
North America 46 (33) 
South America 8 (6) 
Africa 6 (4)  
Central America 4 (3) 
Australia 1 (1) 
Not reported 6 (4) 
 
Trial design  
Parallel 125 (91) 
Crossover 11 (8) 
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Other 2 (1) 
Type of intervention 
Drug 137 (92) 
          Placebo 83 (60) 
          Active drug  36 (26) 
          Usual care  1 (1) 
          Other  7 (5) 
Education or lifestyle 3 (2) 
Nutrition  6 (4) 
Device 2 (1) 
Duration of follow up (median and 
range)b 
24 (0-364) weeks 
aNumber exceeds total as a number of studies were conducted across multiple geographical 
areas.  
b0 Weeks = <24 hour follow up (n=3) 
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Table 2.  Summary of outcomes categorised according to the COMET taxonomy  
Core area 
Core domains Number of trials 
including one or 
more outcome in 
core domain (%) 
Number of 
outcomes 
included in 
core domain 
(%) 
Number of 
trials including 
as a primary 
outcomea  
Death Mortality/survival  3 (2.2) 3 (0.2) 0 
Physiologi
cal/ 
clinical 
Blood and lymphatic system outcomes  9 (6.5) 19 (1.3) 1 
Cardiac outcomes   20 (14.5) 56 (3.9) 9 
Congenital, familial and genetic 
outcomes 
0(0) 0 (0)  
Endocrine outcomes 31(22.5) 50 (3.5) 7 
Ear and labyrinth outcomes 0 (0) 0 (0) 0 
Eye outcomes 2 (1.4) 2 (0.1) 0 
Gastrointestinal outcomes 5 (3.6) 20 (1.4) 2 
General outcomes 65 (47.1) 146 (10.1) 3 
Hepatobiliary outcomes 12 (8.7) 25 (1.7) 3 
Immune system outcomes 28 (20.3) 73 (5.1) 4 
Infection and infestation outcomes 4 (2.9) 8 (0.6) 0 
Injury and poisoning outcomes 0 (0) 0 (0) 0 
Metabolism and nutrition outcomes 121 (87.7) 582 (40.3) 92 
Musculoskeletal and connective tissue 
outcomes 
2 (1.4) 2 (0.1) 1 
Outcomes relating to neoplasms: 
benign, malignant and unspecified 
(including cysts and polyps) 
0 (0) 0 (0) 0 
Nervous system outcomes 6 (4.3) 16 (1.1) 2 
Pregnancy, puerperium and perinatal 
outcomes 
0 (0) 0 (0) 0 
Renal and urinary outcomes 27 (19.6) 76 (5.3) 5 
Reproductive system and breast 0 (0) 0 (0) 0 
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Table 2.  Summary of outcomes categorised according to the COMET taxonomy  
Core area 
Core domains Number of trials 
including one or 
more outcome in 
core domain (%) 
Number of 
outcomes 
included in 
core domain 
(%) 
Number of 
trials including 
as a primary 
outcomea  
outcomes 
Psychiatric outcomes 2 (1.4) 2 (0.1) 0 
Respiratory, thoracic and mediastinal 
outcomes 
3 (2.2) 11 (0.8) 1 
Skin and subcutaneous tissue 
outcomes 
1 (0.7) 1 (0.1) 0 
Vascular outcomes 51 (37) 134 (9.3) 13 
Physical functioning 5 (3.6) 7 (0.5) 0 
Life 
impact 
Social functioning  5 (3.6) 6 (0.4) 0 
Role functioning  3 (2.2) 6 (0.4) 0 
Emotional functioning/wellbeing 8 (5.8) 28 (1.9) 0 
Cognitive functioning 2 (1.4) 22 (1.5) 0 
Global quality of life 4 (2.9) 5 (0.3) 0 
Perceived health status 4 (2.9) 4 (0.3) 0 
Delivery of care  30 (21.7) 60 (4.2) 4 
 Personal circumstance 0 (0) 0 (0) 0 
Resource 
use 
Economic 4 (4) 6 (0.4) 0 
Hospital 3 (2.2) 4 (0.3) 0 
Need for intervention 16 (11.6) 24 (1.7) 1 
Societal/carer burden 0 (0) 0 (0) 0 
Adverse 
Events 
Adverse events/effects 33 (23.9) 46 (3.2) 5 
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Table 3. Summary of Patient Reported Outcome Measures used 
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  Number of trials using PROMs 4 3 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
Core 
domains Outcomes measured by PROM                                                 
Gastrointest
inal 
outcomes 
Nausea/vomiting 
           
X 
           
1 
Fullness/early satiety 
           
X 
           
1 
Bloating 
           
X 
           
1 
General 
outcomes 
Pain   X                 X                         2 
General health   X                                           1 
Metabolism 
and 
nutrition 
outcomes 
Symptomatic hypoglycaemia                               X               1 
Asymptomatic hypoglycaemia                               X               1 
Physical Mobility 
          
X 
            
1 
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Functioning Physical functioning 
 
X 
                     
1 
Energy/fatigue 
 
X 
                   
X 
 
2 
Physical activity 
                
1 
      
1 
Activities of daily living 
      
X X 
               
2 
Usual activities 
          
X 
            
1 
Social 
functioning  
Managing the psychosocial aspects of 
diabetes                                              0 
Quality of Life- social/vocational 
concerns  
        
X 
             
1 
Social functioning 
 
X 
      
X 
              
2 
Quality of Life- general interest                                             X 1 
Role 
functioning 
Role limitations due to physical 
health 
 
X 
                     
1 
Role limitations due to emotional 
problems  X 
                     
1 
Emotional 
functioning/
wellbeing 
Dissatisfaction and readiness to 
change                 X                             1 
Setting and achieving goals 
        
X 
              
1 
Emotional burden 
  
X 
                    
1 
Regimen distress 
  
X 
                    
1 
Interpersonal distress 
  
X 
                    
1 
Physician distress 
  
X 
                    
1 
Anxiety 
          
X 
   
X 
        
2 
Depression 
          
X 
   
X 
    
X 
   
3 
Worries about diabetes 
         
X 
             
1 
Emotional wellbeing 
 
X 
                     
1 
Mood 
                      
X 1 
Vitality 
                      
X 1 
Negative wellbeing 
                     
X 
 
1 
Positive wellbeing 
                     
X 
 
1 
General well being 
                     
X 
 
1 
Fear of hypoglycaemia - behaviour 
             
X 
         
1 
Fear of hypoglycaemia - worry                           X                   1 
Cognitive 
functioning  
Orientation 
            
X 
    
X X 
    
3 
Registration 
                 
X 
     
1 
Attention and calculation 
                 
X 
     
1 
Recall 
                 
X 
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Language 
                 
X X 
    
2 
Attention and concentration  
                  
X 
    
1 
Executive functions 
                  
X 
    
1 
Memory 
            
X 
     
X 
    
2 
Visuoconstructional skills 
                  
X 
    
1 
Conceptual thinking 
                  
X 
    
1 
Calculations 
                  
X 
    
1 
Judgement and problem solving 
            
X 
          
1 
Community affairs 
            
X 
          
1 
Home and hobbies 
            
X 
          
1 
Personal care 
            
X 
          
1 
Subjective memory 
                    
X 
  
1 
Cognitive complaint                                         X     1 
Global 
Quality of 
Life 
Quality of Life -life satisfaction 
         
X 
             
1 
Quality of Life - diabetes impact 
         
X 
             
1 
Perceived 
health 
status Perceived blood glucose control X                                             1 
Delivery of 
Care 
Self-Care Activities - general diet 
   
X X 
                  
2 
Self-Care Activities - specific diet 
   
X X 
                  
2 
Self-Care Activities - medication 
taking 
   
X 
                   
1 
Self-care Activities - blood glucose 
testing  
  
X X 
                  
2 
Self-Care Activities – exercise 
   
X X 
                  
2 
Self-Care Activities - foot care 
   
X X 
                  
2 
Self-Care Activities - smoking 
   
X X 
                  
2 
Self-Care - unspecified 
          
X 
            
1 
Satisfaction with  treatment X 
                      
1 
Patient knowledge of treatment for 
hypoglycaemia  
             
X 
       
 
1 
Medication adherence 
     
X 
                 
1 
Patient knowledge driving and 
hypoglycaemia                              X               1 
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Figure Legends 
 
Figure 1. Flow chart of included trials. 
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PRISMA checklist 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
Included 
in 
abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
3 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
3 and 4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
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Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
4 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
Risk of 
bias was 
not 
assessed 
as the 
focus was 
on 
outcome 
extraction 
only.  
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Not 
applicable 
for this 
review. 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
4 (for 
outcomes 
only) 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Not 
applicable 
for this 
review. 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
Not 
applicable 
for this 
review. 
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RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
Included in 
figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Provided 
in table 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Not 
applicable 
for this 
review of 
outcomes 
used.  
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Not 
applicable 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Meta 
analysis 
not 
completed. 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Not 
applicable 
for this 
review. 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Not 
applicable 
for this 
review. 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
Not 
applicable 
for this 
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review. 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
Page 8.  
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Pages 
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Table 1 Description of included trials 
 N (%) 
Year  
2009 1 (1) 
2010 0 (0) 
2011 2 (1) 
2012 3 (2) 
2013 6 (4)  
2014 21 (15) 
2015 49 (36) 
2016 56 (41) 
  
Phase  
3 48 (35) 
4 90 (65) 
 
Planned enrolment (median and 
range) 
135 (12-5000) 
 
Region of worka 
Asia 55 (40) 
Europe 45 (33) 
North America 46 (33) 
South America 8 (6) 
Africa 6 (4)  
Central America 4 (3) 
Australia 1 (1) 
Not reported 6 (4) 
 
Trial design  
Parallel 125 (91) 
Crossover 11 (8) 
Other 2 (1) 
Type of intervention 
Drug 137 (92) 
          Placebo 83 (60) 
          Active drug  36 (26) 
          Usual care  1 (1) 
          Other  7 (5) 
Education or lifestyle 3 (2) 
Nutrition  6 (4) 
Device 2 (1) 
Duration of follow up (median and 
range)b 
24 (0-364) weeks 
aNumber exceeds total as a number of studies were conducted across multiple geographical 
areas.  
b0 Weeks = <24 hour follow up (n=3) 
 
Table 1 Click here to download Table Table 1 Description of included
trials.docx
Table 2.  Summary of outcomes categorised according to the COMET taxonomy  
Core area 
Core domains Number of trials 
including one or 
more outcome in 
core domain (%) 
Number of 
outcomes 
included in 
core domain 
(%) 
Number of 
trials including 
as a primary 
outcomea  
Death Mortality/survival  3 (2.2) 3 (0.2) 0 
Physiologi
cal/ 
clinical 
Blood and lymphatic system outcomes  9 (6.5) 19 (1.3) 1 
Cardiac outcomes   20 (14.5) 56 (3.9) 9 
Congenital, familial and genetic 
outcomes 
0(0) 0 (0)  
Endocrine outcomes 31(22.5) 50 (3.5) 7 
Ear and labyrinth outcomes 0 (0) 0 (0) 0 
Eye outcomes 2 (1.4) 2 (0.1) 0 
Gastrointestinal outcomes 5 (3.6) 20 (1.4) 2 
General outcomes 65 (47.1) 146 (10.1) 3 
Hepatobiliary outcomes 12 (8.7) 25 (1.7) 3 
Immune system outcomes 28 (20.3) 73 (5.1) 4 
Infection and infestation outcomes 4 (2.9) 8 (0.6) 0 
Injury and poisoning outcomes 0 (0) 0 (0) 0 
Metabolism and nutrition outcomes 121 (87.7) 582 (40.3) 92 
Musculoskeletal and connective tissue 
outcomes 
2 (1.4) 2 (0.1) 1 
Outcomes relating to neoplasms: 
benign, malignant and unspecified 
(including cysts and polyps) 
0 (0) 0 (0) 0 
Nervous system outcomes 6 (4.3) 16 (1.1) 2 
Pregnancy, puerperium and perinatal 
outcomes 
0 (0) 0 (0) 0 
Renal and urinary outcomes 27 (19.6) 76 (5.3) 5 
Reproductive system and breast 
outcomes 
0 (0) 0 (0) 0 
Psychiatric outcomes 2 (1.4) 2 (0.1) 0 
Respiratory, thoracic and mediastinal 
outcomes 
3 (2.2) 11 (0.8) 1 
Skin and subcutaneous tissue 
outcomes 
1 (0.7) 1 (0.1) 0 
Vascular outcomes 51 (37) 134 (9.3) 13 
Physical functioning 5 (3.6) 7 (0.5) 0 
Life 
impact 
Social functioning  5 (3.6) 6 (0.4) 0 
Role functioning  3 (2.2) 6 (0.4) 0 
Emotional functioning/wellbeing 8 (5.8) 28 (1.9) 0 
Cognitive functioning 2 (1.4) 22 (1.5) 0 
Global quality of life 4 (2.9) 5 (0.3) 0 
Perceived health status 4 (2.9) 4 (0.3) 0 
Delivery of care  30 (21.7) 60 (4.2) 4 
Table 2 Click here to download Table Table 2.docx 
Table 2.  Summary of outcomes categorised according to the COMET taxonomy  
Core area 
Core domains Number of trials 
including one or 
more outcome in 
core domain (%) 
Number of 
outcomes 
included in 
core domain 
(%) 
Number of 
trials including 
as a primary 
outcomea  
 Personal circumstance 0 (0) 0 (0) 0 
Resource 
use 
Economic 4 (4) 6 (0.4) 0 
Hospital 3 (2.2) 4 (0.3) 0 
Need for intervention 16 (11.6) 24 (1.7) 1 
Societal/carer burden 0 (0) 0 (0) 0 
Adverse 
Events 
Adverse events/effects 33 (23.9) 46 (3.2) 5 
 
Table 3. Summary of Patient Reported Outcome Measures used 
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  Number of trials using PROMs 4 3 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1   
Core 
domains Outcomes measured by PROM                                                 
Gastrointest
inal 
outcomes 
Nausea/vomiting 
           
X 
           
1 
Fullness/early satiety 
           
X 
           
1 
Bloating 
           
X 
           
1 
General 
outcomes 
Pain   X                 X                         2 
General health   X                                           1 
Metabolism 
and 
nutrition 
outcomes 
Symptomatic hypoglycaemia                               X               1 
Asymptomatic hypoglycaemia                               X               1 
Physical Mobility 
          
X 
            
1 
Table 3 Click here to download Table Table 3.docx 
Functioning Physical functioning 
 
X 
                     
1 
Energy/fatigue 
 
X 
                   
X 
 
2 
Physical activity 
                
1 
      
1 
Activities of daily living 
      
X X 
               
2 
Usual activities 
          
X 
            
1 
Social 
functioning  
Managing the psychosocial aspects of 
diabetes                                              0 
Quality of Life- social/vocational 
concerns  
        
X 
             
1 
Social functioning 
 
X 
      
X 
              
2 
Quality of Life- general interest                                             X 1 
Role 
functioning 
Role limitations due to physical 
health 
 
X 
                     
1 
Role limitations due to emotional 
problems  X 
                     
1 
Emotional 
functioning/
wellbeing 
Dissatisfaction and readiness to 
change                 X                             1 
Setting and achieving goals 
        
X 
              
1 
Emotional burden 
  
X 
                    
1 
Regimen distress 
  
X 
                    
1 
Interpersonal distress 
  
X 
                    
1 
Physician distress 
  
X 
                    
1 
Anxiety 
          
X 
   
X 
        
2 
Depression 
          
X 
   
X 
    
X 
   
3 
Worries about diabetes 
         
X 
             
1 
Emotional wellbeing 
 
X 
                     
1 
Mood 
                      
X 1 
Vitality 
                      
X 1 
Negative wellbeing 
                     
X 
 
1 
Positive wellbeing 
                     
X 
 
1 
General well being 
                     
X 
 
1 
Fear of hypoglycaemia - behaviour 
             
X 
         
1 
Fear of hypoglycaemia - worry                           X                   1 
Cognitive 
functioning  
Orientation 
            
X 
    
X X 
    
3 
Registration 
                 
X 
     
1 
Attention and calculation 
                 
X 
     
1 
Recall 
                 
X 
     
1 
Language 
                 
X X 
    
2 
Attention and concentration  
                  
X 
    
1 
Executive functions 
                  
X 
    
1 
Memory 
            
X 
     
X 
    
2 
Visuoconstructional skills 
                  
X 
    
1 
Conceptual thinking 
                  
X 
    
1 
Calculations 
                  
X 
    
1 
Judgement and problem solving 
            
X 
          
1 
Community affairs 
            
X 
          
1 
Home and hobbies 
            
X 
          
1 
Personal care 
            
X 
          
1 
Subjective memory 
                    
X 
  
1 
Cognitive complaint                                         X     1 
Global 
Quality of 
Life 
Quality of Life -life satisfaction 
         
X 
             
1 
Quality of Life - diabetes impact 
         
X 
             
1 
Perceived 
health 
status Perceived blood glucose control X                                             1 
Delivery of 
Care 
Self-Care Activities - general diet 
   
X X 
                  
2 
Self-Care Activities - specific diet 
   
X X 
                  
2 
Self-Care Activities - medication 
taking 
   
X 
                   
1 
Self-care Activities - blood glucose 
testing  
  
X X 
                  
2 
Self-Care Activities – exercise 
   
X X 
                  
2 
Self-Care Activities - foot care 
   
X X 
                  
2 
Self-Care Activities - smoking 
   
X X 
                  
2 
Self-Care - unspecified 
          
X 
            
1 
Satisfaction with  treatment X 
                      
1 
Patient knowledge of treatment for 
hypoglycaemia  
             
X 
       
 
1 
Medication adherence 
     
X 
                 
1 
Patient knowledge driving and 
hypoglycaemia                              X               1 
 
  
675 entries returned 
354 entries reviewed 
Duplicates removed 
321 
138 entries reviewed and 
outcomes extracted 
Excluded: 216 
Type 1 diabetes: 19 
Prevention: 5 
Phase 2:  26 
Pharmacokinetics: 2 
Paediatric population:  10 
Other condition: 15 
Not an RCT: 32 
Hospitalisation or generic surgery: 11 
Healthy participants: 9 
Gestational diabetes : 9 
Treatment of a co-
morbidity/complication :73 
Bariatric surgery: 5 
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